Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.
AusCann Group Holdings Ltd’s (ASX:AC8) search for a new chief executive officer is progressing to plan and is now at an advanced stage.
The board has selected a final shortlist and is confident in the high calibre of Australian and international candidates that it believes have the necessary skills and experience to guide AusCann through its next phase of growth as a pharmaceutical manufacturing and sales business.
AusCann is expected to make an appointment once final interviews have been completed early in the new year.
Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.
READ: AusCann Group appoints Paul MacLeman as executive director
Dr MacLeman is an experienced pharmaceutical executive and has been a senior consultant to AusCann since October 2017. He is leading the board’s executive CEO search process.
AusCann managing director Elaine Darby said: “The CEO search process is progressing very well and is now nearing completion.
“The transition is a natural evolution that reflects the continued growth and development of AusCann, and the board has worked to ensure it is a well planned and orderly one.
READ: AusCann Group appoints PCI Pharma to manufacture first product line
“I am extremely proud of what we have achieved at AusCann since the inception of the company in 2014 and listing in early 2017, including our licensing, cultivation, and product development activities which have culminated into our hard shell capsules soon to be commercialised.
“I am confident AusCann will go from strength to strength as it moves into a manufacturing and marketing footing for our first-generation product range.
“We see innovation and continued new product development as key to the next stages of the company’s development.”
